by John Conrad | Dec 3, 2024 | Member News
COUR Pharmaceuticals has secured a strategic collaboration and licensing agreement with Genentech, a member of the Roche Group, to develop and commercialize its tolerogenic nanoparticle treatments for autoimmune conditions. The partnership, announced via press release...
by John Conrad | Aug 5, 2024 | NewsBrief
COUR Pharmaceuticals, a clinical-stage biotech company focused on developing treatments for autoimmune and inflammatory diseases, has announced a significant leadership transition. Founder John J. Puisis will step down as President and Chief Executive Officer, handing...
